Loading...
•
Dec 31, 2024
Bioventus Q4 2024 Earnings Report
Bioventus reported strong revenue growth and improved profitability in Q4 2024.
Key Takeaways
Bioventus achieved a 13.5% increase in revenue for Q4 2024, driven by double-digit growth in Pain Treatments and Surgical Solutions. The company posted an adjusted EBITDA of $28.3 million, up 28.3% year-over-year. Non-GAAP EPS rose to $0.15 from $0.07 in the prior year. Net loss from continuing operations significantly improved to $0.3 million compared to $7.7 million in Q4 2023.
Q4 revenue increased by 13.5% year-over-year to $153.6 million.
Adjusted EBITDA grew 28.3% to $28.3 million, reflecting higher profitability.
Non-GAAP EPS rose to $0.15 per share from $0.07 in the previous year.
Net loss from continuing operations significantly narrowed to $0.3 million.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Bioventus expects full-year 2025 revenue of $560M to $570M, reflecting 6.1% to 8.0% organic growth, alongside a projected adjusted EBITDA margin expansion.
Positive Outlook
- Full-year 2025 revenue expected to reach $560M to $570M.
- Projected organic revenue growth of 6.1% to 8.0%.
- Adjusted EBITDA expected to grow to $112M - $116M.
- Non-GAAP EPS forecasted to increase by 30.6% to 38.8%.
- Ongoing operational improvements expected to enhance profitability.
Challenges Ahead
- Guidance excludes potential acquisitions and divestitures.
- Macroeconomic headwinds may impact overall growth.
- Increasing competition in pain treatment and surgical solutions.
- Potential regulatory changes could affect market positioning.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...